Supernus Pharmaceuticals will merge with Indivior in a tax-free all-stock deal, creating a CNS-focused company with $2.2bn ...

NAUT is now prioritizing targeted proteoform assays after Broadscale testing failed to support its prior commercialization ...

The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance ...

New research shows that almost half of the ASX listed biotechs have a cash runway of less than a year. Can they make it to ...

Researchers at the Indian Institute of Technology Gandhinagar (IITGN) and the Regional Centre for Biotechnology, Faridabad, ...

Biotech is entering its next phase of growth, where the competitive landscape may increasingly be determined by what happens ...

Georgia Witchel's Mantis Biotech makes Parva, consumer software that reads how a person types and clicks to flag cognitive ...

A growing number of mainland Chinese institutional fund managers have built up stakes in Hong Kong-listed biotechnology stocks over the past month, drawn by attractive valuations amid a surge in cross ...

LLY beat Q1 EPS estimates by 26% and launched Foundayo, while beaten-down NVO trades near 10x earnings and 45% below its 52-week high. Viking's pre-revenue VKTX carries binary Phase 3 risk, but VK2735 ...

Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...

Belgium’s biotech sector has the science but not the scale, according to a new PwC whitepaper, which argues that the country must operate as one ecosystem if startups are to grow. PwC’s whitepaper, ...